Praxis Precision Medicine's Options: A Look at What the Big Money is Thinking - Praxis Precision Medicine (NASDAQ:PRAX)
PraxisPraxis(US:PRAX) Benzinga·2025-12-05 19:01

Core Viewpoint - Investors with significant capital have adopted a bearish stance on Praxis Precision Medicine, indicating potential upcoming developments that may impact the stock [1][2]. Options Trading Activity - Benzinga's options scanner identified 21 unusual options trades for Praxis Precision Medicine, with a split sentiment of 38% bullish and 47% bearish among large investors [2][3]. - The total amount for put options reached $481,965, while call options totaled $1,290,815, suggesting a stronger interest in bullish positions despite the overall bearish sentiment [3]. Predicted Price Range - Over the last three months, large investors have targeted a price range for Praxis Precision Medicine between $65.0 and $300.0 based on volume and open interest in options contracts [4]. Volume and Open Interest Analysis - An analysis of volume and open interest reveals crucial insights into liquidity and interest levels for Praxis Precision Medicine's options, particularly within the strike price range of $65.0 to $300.0 over the past month [5]. Current Market Status - In the last month, five experts provided ratings on Praxis Precision Medicine, with an average target price of $203.2, indicating a generally positive outlook despite mixed sentiments [14]. - Analysts from HC Wainwright & Co. maintain a Buy rating with a target price of $340, while another analyst from the same firm downgraded to a Buy with a target of $258 [15]. - Wedbush analysts have a more cautious view, maintaining an Underperform rating with target prices of $83 and $77 [15]. Company Overview - Praxis Precision Medicine is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with three clinical-stage product candidates and one in-licensed candidate [12].

Praxis Precision Medicine's Options: A Look at What the Big Money is Thinking - Praxis Precision Medicine (NASDAQ:PRAX) - Reportify